



IMMUNOASSAY MARKETS

Strategies and Trends. Forecasts by Instrument Type and by Application and by Country. With Multiplex and Point of Care Market Analysis, Executive Guides and including Customized Forecasting and Analysis.

2019 to 2023



Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

Table of Contents

i. Immunoassay Market - Strategic Situation Analysis	12
ii. Guide for Executives, Marketing, Sales and Business Development Staff	13
iii. Guide for Management Consultants and Investment Advisors	14
1. Introduction and Market Definition	15
1.1 Immunoassay Markets Definition In This Report	16
1.1.1 Enzyme Based	16
1.1.2 Immunofluorescence	17
1.1.3 Chemiluminescence	17
1.1.4 DNA/NAT	17
1.1.5 RIA & Other	17
1.1.6 Reagents/Kits, Analyzers, Software & Services	17
1.1.7 Infectious Disease	18
1.1.8 Auto Immune	18
1.1.9 Endocrinology	18
1.1.10 Oncology	18
1.1.11 Cardiology	18
1.1.12 Other Specialty	18
1.2 Market Definition	19
1.2.1 Market Sizes	19
1.2.2 Currency	19
1.2.3 Years	19
1.3 Methodology	20
1.3.1 Authors	20
1.3.2 Sources	20
1.4 U.S. Medical Market and Clinical Laboratory Testing - Perspective	22

1.4.1 U.S. Medicare Expenditures for Clinical Testing	23
2. Industry Overview	25
2.1 Industry Participants	26
2.1.1 IVD Supplier	26
2.1.2 Independent lab specialized/esoteric	27
2.1.3 Independent lab national/regional	27
2.1.4 Independent lab analytical	28
2.1.5 Public National/regional lab	28
2.1.6 Hospital lab	28
2.1.7 Physician lab	29
2.1.8 Audit body	29
2.2 The Clinical Laboratory Market Segments	31
2.2.1 Traditional Market Segmentation	31
2.2.2 Laboratory Focus and Segmentation	32
2.2.3 Hospital Testing Share	34
2.2.4 Economies of Scale	34
2.2.4.1 Hospital vs. Central Lab	35
2.2.5 Physician Office Lab's	36
2.2.6 Physician's and POCT	36
2.3 Immunoassay –Markets and Discussion	37
2.3.1 Instruments – Genetics changes the picture	37
2.3.1.1 RIA – A Technology Shows its Age	38
2.3.1.2 Immunoassay vs. PCR vs. Sequencing – A See Saw Battle	38
2.3.1.3 The Smart Shrinking Instrument – Serious Implications	39
2.3.1.4 Research Funding and Capital Expense – Instrument Pooling	39
2.3.1.4 Multiplex vs. POC – A Tradeoff Analysis	40
2.3.2 Reagents and Kits – Genetics changes the picture	40
2.3.1.1 Bigger Test Menus a Boon for Kit Market	41

2.3.3 Physician Office Labs – A New Frontier	41
2.3.4 Rapid and POCT to Threaten Instrument Markets	41
2.3.5 OTC and DTC – Huge Market Potential	42
2.3.6 Economies of Scale. Going Away?	42
2.3.7 Lower Barriers to Entry for Instruments/Analyzers	43
2.3.8 Miniturization and Technology Drive Acquisition	43
2.4 Profiles of Key Companies	44
2.4.1 Abbott Diagnostics	45
2.4.2 Abcam	46
2.4.3 Arlington Scientific	47
2.4.4 Awareness Technology	48
2.4.5 Beckman Coulter, Inc	49
2.4.7 Becton Dickinson	50
2.4.7 BioCartis	51
2.4.8 bioMerieux	52
2.4.9 Bioneer	53
2.4.10 Bio-Rad Laboratories	55
2.4.11 Biotek	57
2.4.12 Boditech Med, Inc	58
2.4.13 Boster Biological Technology	59
2.4.14 Diamedix (Erba Diagnostics)	60
2.4.15 Diasorin S.p.A.	62
2.4.16 Dynex Technologies	63
2.4.17 Fujirebio	64
2.4.18 Gold Standard Diagnostics	65
2.4.21 Grifols	66
2.4.22 Hycor Biomedical	67
2.4.23 Immunodiagnostic Systems (IDS)	68

2.4.24 Immunodiagnostik AG	69
2.4.25 Inova Diagnostics	70
2.4.26 JR Biomedical.....	71
2.4.27 Luminex Corp	72
2.4.28 Meso Scale Discovery	73
2.4.29 Molecular Devices	74
2.4.30 MP Biomedical.....	75
2.4.31 MyCartis	76
2.4.32 Ortho Clinical Diagnostics.....	77
2.4.33 PerkinElmer	78
2.4.34 Qiagen.....	79
2.4.35 Randox Toxicology	81
2.4.36 R&D Systems	82
2.4.37 Roche Molecular Diagnostics	83
2.4.38 Seramatrix	85
2.4.39 Siemens Healthineers.....	86
2.4.40 Sigma Aldrich (now Millipore Sigma).....	88
2.4.41 Tecan	89
2.4.42 Thermo Fisher Scientific Inc.	90
2.4.43 TOSOH Bioscience.....	92
2.4.44 Wako Diagnostics	93
3. Market Trends.....	94
3.1 Factors Driving Growth	95
3.1.1 Diagnostic Factors	95
3.1.2 Changing Technologies Spur Early Instrument Retirement.....	95
3.1.3 Consumer Channels Open Wider.	96
3.1.4 Immunity Technology Comes of Age	96
3.2 Factors Limiting Growth	97

3.2.1 Increased Competition Lowers Price	97
3.2.2 Threat from PCR Based Instruments.	98
3.2.3 Lower Barriers to Entry.	98
3.2.4 Wellness has a downside	98
3.3 Immunoassay Instrumentation	99
3.3.1 Instrumentation Tenacity.....	99
3.3.2 Declining Cost of Instruments Changes Industry Structure.	99
3.3.3 LISTING of CURRENT INSTRUMENT SPECIFICATIONS.....	100
3.3.4 Immunoassay – CRISPR Diagnostics.....	111
4. Immunoassay Recent Developments.....	112
4.1 Recent Developments – Importance and How to Use This Section.....	113
4.1.1 Importance of These Developments	113
4.1.2 How to Use This Section.....	113
4.2 Russian Researchers Develop Rapid Test for Heart Attack	113
4.3 Quidel Full-Year 2017 Revenues Spike on Triage Acquisition	114
4.4 Bruker Announces Acquisition of Field-Portable Platform	115
4.5 Beckman Coulter Goes to Court to Sell its BNP Assay	116
4.6 DiaSorin to buy Siemens' ELISA Immunodiagnosics Business	117
4.8 Erba Dx Acquires Calbiotech	117
4.9 Quidel Closes \$14M Acquisition of POC Eye Health Businesses.....	118
4.10 Precision for Medicine Buys Immune Monitoring Lab Epiontis	118
4.11 Immunalysis Receives FDA Clearance for SEFRIA™ Fentanyl Urine Drug Screening Test..	119
4.12 Zimmer buys CD Diagnostics to gain musculoskeletal Dx.....	120
4.14 Abcam, Molecular Devices join forces to develop immunoassays.....	120
4.15 Qiagen inks \$191M deal to buy infection test panel firm STAT-Dx.....	121
4.16 Roche pens septic shock diagnostic pact.....	122
4.17 Mologic grabs CE mark for POC vaginosis test.....	123
4.18 Over-the-counter HIV test earns CE mark.....	123

4.19 Beckman Coulter receives clearance for AMH Immunoassay	124
4.20 Abbott receives clearance for Next-gen Diagnostic Systems	125
4.22 Beckman Coulter - Enhancements of Access 2 IA System	126
4.23 New handheld spectral analyzer uses power of smartphone to detect disease	127
4.24 Quanterix to Launch High-Sensitivity Benchtop Multiplex Instrument.....	128
5. The Global Market	130
5.1 Global Market by Country	131
6. Global Market by Application.....	133
6.1 Global Market by Application	134
6.2 Endocrinology Applications	136
6.3 Immune Applications.....	138
6.4 Oncology Applications	140
6.5 Infectious Disease Applications	142
6.5 Cardiology Applications	144
6.6 Other Applications	146
7. Immunoassay by Technology.....	148
7.1 Global Market by Technology	149
7.2 Enzyme.....	152
7.3 Fluorescence	154
7.4 Chemiluminescence	156
7.5 Nucleic Acid.....	158
7.6 Rapid/POC	160
7.7 Radioimmunoassay and Other.....	162
8. Vision of the Future of Immunoassay	164
Appendices.....	165
I. United States Medicare System: January 2018 laboratory Fees Schedule – National Limit and Midpoint.....	165

Table of Tables

TABLE 1 MEDICARE CLINICAL LAB EXPENDITURES ACTUAL & FORECAST 2004 TO 2020 (\$BILLION)	24
Table 2 Market Players by Type.....	26
Table 3 Clinical Laboratory Departments and Segments.....	31
Table 4 Laboratory Management Focus – Different Approaches.....	32
Table 5 Key Segmentation Variables Going Forward.....	33
Table 6 The Different Markets for Immunoassay.....	37
Table 7 The Factors Driving Growth.....	95
Table 8 Factors Limiting Growth	97
Table 9 - Listing of Current Instrument Specifications	100
Table 10 The Global Immunoassay Market by Country.....	131
Table 11 Global Market by Application.....	134
Table 12 Endocrinology Immunoassay by Country	136
Table 13 Immune Immunoassay by Country	138
Table 14 Oncology Immunoassay by Country.....	140
Table 15 Infectious Disease Immunoassay by Country	142
Table 16 Cardiology Immunoassay by Country.....	144
Table 17 Other Immunoassay by Country.....	146
Table 18 Global Market by Technology.....	149
Table 19 Enzyme Immunoassay by Country.....	152
Table 20 Fluorescence by Country	154
Table 21 Chemiluminescence by Country.....	156
Table 22 Nucleic Acid by Country	158
Table 23 Rapid/POC by Country.....	160
Table 24 RIA and Other by Country	162

Table 25 2018 Clinical Lab Fee Schedule 165

Table of Figures

FIGURE 1 MEDICARE CLINICAL LAB EXPENDITURES 2004 TO 2020 (\$MILLION) 23

Figure 2 Immunoassay - Key Countries 132

Figure 3 Chart of Growth by Application..... 135

Figure 4 Chart – Endocrinology Immunoassay by Country..... 137

Figure 5 Chart - Immune Immunoassay by Country 139

Figure 6 Chart - Oncology Immunoassay by Country..... 141

Figure 7 Chart - Infectious Disease Immunoassay by Country..... 143

Figure 8 Chart - Cardiology Immunoassay by Country..... 145

Figure 9 Chart - Other Immunoassay by Country 147

Figure 10 Chart of Growth by Technology..... 150

Figure 11 Chart - Technology Change in Planning Period..... 151

Figure 12 Chart - Enzyme by Country 153

Figure 13 Chart - Flourescence by Country..... 155

Figure 14 Chart - Chemiluminesence by Country..... 157

Figure 15 Chart - Nucleic Acid by Country 159

Figure 16 Chart – Rapid/POC by Country..... 161

Figure 17 Chart – RIA and Other by Country 163